The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study

NCT06125080 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

78

Enrollment

OTHER

Sponsor class

Conditions

TNBC - Triple-Negative Breast Cancer

Interventions

DRUG: Utidelone
DRUG: Tirelizumab
DRUG: Bevacizumab

Sponsor

Huihua Xiong